Publications by authors named "Habimana Y"
Article Synopsis
- Multidrug-resistant tuberculosis (MDR-TB), identified by rifampicin resistance (RR), poses significant challenges in managing TB in Rwanda, requiring investigation into its transmission dynamics over 27 years.
- The study involved analyzing the whole genome sequences of RR-TB isolates from three periods: before MDR-TB program management (1991-2005), during early program management (2006-2013), and during a more consolidated phase (2014-2018) when rifampicin drug-susceptibility testing was expanded.
- The results identified 13 transmission clusters among RR-TB isolates, with a dominant clone named "Rwanda Rifampicin-Resistant clone" (R3clone) being responsible for 69.
Article Synopsis
- Two cases are discussed where the Xpert MTB/RIF test incorrectly indicated rifampicin-resistant tuberculosis.
- This false result was linked to low cycle thresholds and missing probes in the test.
- The findings suggest a need for improvements in the Xpert MTB/RIF testing method.
We report a case of acquired fluoroquinolone (FQ) resistance under short-course multidrug-resistant tuberculosis (MDR-TB) treatment. The patient was managed at Kabutare hospital, one of the two specialized MDR-TB clinics in Rwanda. A low dose of moxifloxacin was used in the first three critical months.
View Article and Find Full Text PDFThe human- and animal-adapted lineages of the Mycobacterium tuberculosis complex (MTBC) are thought to have expanded from a common progenitor in Africa. However, the molecular events that accompanied this emergence remain largely unknown. Here, we describe two MTBC strains isolated from patients with multidrug resistant tuberculosis, representing an as-yet-unknown lineage, named Lineage 8 (L8), seemingly restricted to the African Great Lakes region.
View Article and Find Full Text PDFArticle Synopsis
- The Xpert MTB/RIF assay is widely used to quickly diagnose tuberculosis and identify rifampicin resistance, but this study examines how often false-positive rifampicin resistance results occur.
- Conducted in Rwanda, the study involved patients with initial positive results and included repeat testing and advanced sequencing to clarify actual resistance status.
- Of the 154 patients retested, 47% were found to have false-positive results for rifampicin resistance, while a subset of those with true resistance also had issues being confirmed by the initial Xpert test.
In 2005, in response to the increasing prevalence of rifampicin-resistant tuberculosis (RR-TB) and poor treatment outcomes, Rwanda initiated the programmatic management of RR-TB, including expanded access to systematic rifampicin drug susceptibility testing (DST) and standardised treatment. To describe trends in diagnostic and treatment delays and estimate their effect on RR-TB mortality. Retrospective analysis of individual-level data including 748 (85.
View Article and Find Full Text PDF